Skip to content
The Nexus
DossierENTITY

M42

Coverage of M42 in the Nexus archive.

Earliest in view: May 13 · 11:21 UTCMost recent: Jul 28 · 11:07 UTC
Co-mentioned in this coverage
Abu Dhabiplace2Insilico Medicineorganization1Alex Zhavoronkovperson1UAEplace1AI computing powertopic1GLP-1 drugstopic1Mubadalaorganization1Dimitris Moulavasilisperson1G42organization1Diaverumorganization1Emirati Genome Programtopic1Uzbekistanplace1
Recent coverage
  • HEALTHJul 28 · 11:07 UTCSEMAFOR
    Abu Dhabi lab advances AI search for non-opioid painkillers

    Insilico Medicine, a biotech firm, leverages Abu Dhabi's AI computing resources to develop a non-opioid painkiller candidate, its second from the UAE facility. The drug, nearing human trials, could revolutionize pain treatment and is part of Abu Dhabi's broader strategy to attract biotech innovation through investments and infrastructure.

  • HEALTHMay 13 · 11:21 UTCSEMAFOR
    Mubadala-backed M42 pitches genomics capabilities to the world

    M42, an Abu Dhabi healthcare company backed by Mubadala, is pitching its genomic sequencing capabilities to governments and pharmaceutical companies worldwide. The firm has sequenced nearly 1 million genetic samples and is launching AI chatbots for chronic disease management, starting with kidney.com. M42 plans to expand its data-driven healthcare model globally and develop additional condition-specific platforms.